论文部分内容阅读
目的评估奥施康定治疗癌疼痛的有效性和安全性。方法 (1)文献检索:从Cochrane library、PubMed,Embase、CBM、CNKI、维普数据库检索关于奥施康定治疗癌疼痛有效性和安全性的文献。(2)Meta分析:应用Rev Man 5.0软件对入选的文献进行Meta分析,奥施康定与其他类型阿片类药物的有效性和安全性的差异用OR值评估和95%可信区间表示。结果共检索出相关文献32篇,按纳入标准和排除标准筛选出5项研究文献,共456例癌疼痛患者纳入研究。Meta分析结果显示,奥施康定治疗癌疼痛的有效性与其他强阿片类药物比较无统计学差异(OR:1.68;95%CI:0.86~3.26;P=0.13);副作用发生率亦无统计学差异。结论奥施康定与其他强阿片类药物在治疗癌疼痛的有效性和安全性无统计学差异。
Objective To evaluate the efficacy and safety of OxyContin in the treatment of cancer pain. Methods (1) Literature search: The literature about the efficacy and safety of OxyCardin in the treatment of cancer pain was retrieved from Cochrane library, PubMed, Embase, CBM, CNKI and VIP databases. (2) Meta-analysis: Meta-analysis was performed on the selected literature using RevMan 5.0 software. Differences in the validity and safety of Oxycycline with other types of opioids were evaluated using OR and 95% confidence intervals. Results A total of 32 articles were retrieved. Five research articles were screened by inclusion criteria and exclusion criteria. A total of 456 cases of cancer pain were included in the study. Meta-analysis showed that the effectiveness of OxyContin in the treatment of cancer pain was not statistically different from other strong opioids (OR: 1.68; 95% CI: 0.86 to 3.26; P = 0.13); the incidence of side effects was also not statistically significant difference. Conclusion Oxycodin and other strong opioids in the treatment of cancer pain, the effectiveness and safety were not statistically different.